Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling.

MLA

Bakbak, Ehab, et al. “Empagliflozin Improves Circulating Vascular Regenerative Cell Content in People without Diabetes with Risk Factors for Adverse Cardiac Remodeling.” American Journal of Physiology: Heart & Circulatory Physiology, vol. 325, no. 5, Nov. 2023, pp. 1210–22. EBSCOhost, https://doi.org/10.1152/ajpheart.00141.2023.

APA

Bakbak, E., Verma, S., Krishnaraj, A., Quan, A., Chao-Hung Wang, Yi Pan, Puar, P., Mason, T., Verma, R., Terenzi, D. C., Rotstein, O. D., Yan, A. T., Connelly, K. A., Hwee Teoh, Mazer, C. D., & Hess, D. A. (2023). Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling. American Journal of Physiology: Heart & Circulatory Physiology, 325(5), 1210–1222. https://doi.org/10.1152/ajpheart.00141.2023

Chicago

Bakbak, Ehab, Subodh Verma, Aishwarya Krishnaraj, Adrian Quan, Chao-Hung Wang, Yi Pan, Pankaj Puar, et al. 2023. “Empagliflozin Improves Circulating Vascular Regenerative Cell Content in People without Diabetes with Risk Factors for Adverse Cardiac Remodeling.” American Journal of Physiology: Heart & Circulatory Physiology 325 (5): 1210–22. doi:10.1152/ajpheart.00141.2023.